Company intelligence / Profile preview
Ossianix
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Developing biological drugs from shark single domain antibodies with a focus on blood-brain barrier penetrant biologics. Their TXP1 Brain Shuttle enhances delivery of therapeutic payloads to the brain by >30-fold.
- Therapeutic areas
- Metabolic DisordersEndocrinologyOncologyNeurologyInfectious Diseases
- Modalities
- Single domain antibodiesBispecific antibodiesTrispecific antibodiesRecombinant polypeptides
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ossianix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ossianix.